Lindbrook Capital, LLC Nkarta, Inc. Transaction History

Lindbrook Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	SELL	$5.27 - $10.82 $484 - $995	-92 Reduced 55.76%	73 $0
Q1 2024 Apr 25, 2024	BUY	$5.59 - $15.71 $922 - $2,592	165 New	165 $1,000
Q3 2022 Nov 10, 2022	SELL	$12.27 - $18.39 $208 - $312	-17 Reduced 8.5%	183 $2,000
Q2 2022 Aug 01, 2022	BUY	$7.77 - $19.44 $132 - $330	17 Added 9.29%	200 $2,000
Q1 2022 Apr 21, 2022	SELL	$8.66 - $14.99 $103 - $179	-12 Reduced 6.15%	183 $2,000
Q4 2021 Jan 18, 2022	BUY	$12.79 - $26.88 $2,494 - $5,241	195 New	195 $3,000
Q3 2021 Nov 05, 2021	SELL	$26.67 - $38.76 $4,667 - $6,783	-175 Closed	0 $0
Q4 2020 Jan 27, 2021	SELL	$27.03 - $75.62 $81,090 - $226,860	-3,000 Reduced 94.49%	175 $11,000
Q3 2020 Nov 03, 2020	BUY	$23.52 - $47.9 $74,676 - $152,082	3,175 New	3,175 $95,000

129

66.5M

173K

20K

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $127M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.